Asia Pacific Cancer Immunotherapy Market Size to register a growth of 16.5% CAGR

20-11-2018 | Report Format: Electronic (PDF)

Growth, Trends and Report Highlights

According to a new report Asia Pacific Cancer Immunotherapy Market, published by KBV research, the Asia Pacific Cancer Immunotherapy Market would witness market growth of 16.5% CAGR during the forecast period (2018 – 2024).

The Monoclonal Antibodies market dominated the Asia Pacific Cancer Immunotherapy Market by Technology 2017, thereby, achieving a market value of $17,081.5 million by 2024, The Cytokines & Immunomodulators market is expected to witness a CAGR of 15% during (2018 - 2024). Additionally, The Other Technology market is expected to witness highest CAGR of 17.5% during (2018 - 2024).

The Japan market would dominate the Asia Pacific Cancer Immunotherapy Lung Cancer Market by 2024; growing at a CAGR of 13.4 % during the forecast period. The China market is expected to witness a CAGR of 13.8% during (2018 - 2024). Additionally, The India market is expected to witness a CAGR of 18.5% during (2018 - 2024).

The Hospitals market dominated the India Cancer Immunotherapy Market by End User 2017 thereby, achieving a market value of $4,415.2 million by 2024. The Clinics market is expected to witness a CAGR of 19.5% during (2018 - 2024). Additionally, The Other End User market is expected to witness highest CAGR of 20.1% during (2018 - 2024).

Full Report: https://www.kbvresearch.com/asia-pacific-cancer-immunotherapy-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd